HealthStream (HSTM) sets the stage with steady top line and mixed earnings signals

HealthStream (HSTM) has kicked off its Q1 2026 earnings season with a recent track record that shows quarterly revenue ranging from about US$73.5 million to US$79.7 million over 2025, alongside basic EPS between roughly US$0.09 and US$0.21. Over the same period, the company has seen revenue move from US$73.1 million in Q3 2024 to US$79.7 million in Q4 2025. Trailing twelve month EPS has sat between about US$0.61 and US$0.68. This sets up a story where modest top line growth meets tighter margins and leaves investors weighing the trade off between revenue resilience and earnings pressure.

See our full analysis for HealthStream.

With that context in place, the next step is to set these results against the widely shared narratives about HealthStream to see which stories the numbers support and which ones they call into question.

Margins soften as net profit margin slips to 6%

• Over the last 12 months, HealthStream converted US$304.1 million of revenue into US$18.3 million of net income, which works out to a 6% net profit margin compared with 6.9% a year earlier.
• Bears argue that rising platform and cloud costs will keep squeezing profitability, and the margin data gives them some support, yet it also leaves room for debate:
  • The bearish narrative highlights higher cloud hosting and product modernization costs as a drag on margins, and the move from 6.9% to 6% net margin over the year fits that concern.
  • At the same time, trailing twelve month earnings of US$18.3 million still sit above the most recent single quarter net income of US$2.5 million, so bears need to factor in that the longer record is more resilient than the latest quarter alone.

Bears who worry about margin pressure may want to see how this quarter's softer profitability lines up with the more cautious long term narrative for HealthStream. 🐻 HealthStream Bear Case

4.7% revenue growth trails wider US market

• Revenue over the last year grew 4.7% to about US$304.1 million, compared with the broader US market growth rate of 11.2% per year.
• Supporters of the consensus narrative see digital healthcare trends as a long term tailwind, but the current growth rate gives a more restrained picture:
  • Consensus commentary links digital transformation and regulatory complexity to expected sustained revenue growth, yet the 4.7% revenue growth figure sits well below the 11.2% wider market pace, so any catch up story still needs to show up in the numbers.
  • Quarterly revenue rising from US$73.1 million in Q3 2024 to US$79.7 million in Q4 2025 indicates a steady top line, which partially counters the bearish worry that legacy product runoff is overwhelming newer SaaS products.

P/E of 38.9x and DCF fair value US$32.91 create valuation tension

• At a P/E of 38.9x, the stock trades below its peer group average of 43.5x but above the Global Healthcare Services industry average of 28.1x, while the current share price of US$24.36 sits below the DCF fair value of about US$32.91.
• Bulls point to platform growth and acquisitions to justify upside, and the valuation data partly backs that view but also sets a high bar:
  • The bullish narrative talks about hStream driven recurring revenue and potential M&A as earnings drivers, and the roughly US$8.55 gap between the share price and the DCF fair value suggests the model sees room for better fundamentals than today.
  • However, with trailing earnings growth turning negative over the last year and revenue growing 4.7% against an 11.2% market rate, investors relying on the bullish case need to be comfortable that future execution will support a P/E that remains above the broader industry.

Bulls who view the current P/E and DCF gap as an opening can walk through the full optimistic case for how HealthStream's platform and earnings profile might support that view. 🐂 HealthStream Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for HealthStream on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of steady revenue and tighter margins leaves you unsure, it is worth reviewing the numbers yourself and deciding where you stand. To help frame that view, take a closer look at the company's 1 key reward

See What Else Is Out There

HealthStream currently pairs a 4.7% revenue growth rate that trails the wider US market with a softer 6% net margin and negative trailing earnings growth.

If that mix of slower growth and compressed profitability feels limiting, you can quickly compare it with companies that currently screen as 51 high quality undervalued stocks and might offer a more attractive balance of price and potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.